Abstract Body

Background: Physiological changes during pregnancy coupled with single nucleotide polymorphisms (SNPs) in drug disposition genes are known to alter the pharmacokinetics (PK) of many drugs. In the present study the magnitude of pregnancy-induced changes in efavirenz (EFV) PK in genetically-defined subgroups was investigated.

Methods: This was an observational study with an enrichment design conducted in two phases. In the preliminary phase, we explored associations between selected CYP2B6, NR1I3, CYP2A6, and ABCB1 SNPs and mid-dose EFV concentrations in an unselected cohort of HIV positive women during pregnancy and postpartum. In the second phase, patients were stratified according to CYP2B6 516G>T (rs3745274). Accordingly, randomly selected patients in each genotype group were invited for the intensive PK phase; samples were collected at 0.5, 1, 2, 4, 8, 12 and 24 hours after an observed evening dose of EFV.

Results: A total of 211 HIV positive women taking EFV-based regimens for prevention of mother-to-child transmission (PMTCT) of HIV during pregnancy (n = 77) or postpartum (n = 134) were recruited. Of the nine SNPs investigated, only CYP2B6 516G>T was independently associated with EFV plasma concentrations during both pregnancy and postpartum and was used to pre-select patients for the intensive PK phase. A global comparison showed a 42.6% increase in CL/F (p = 0.02), 29.8% reduction in AUC0-24 (p = 0.02) and 50.7% reduction in Cmin (p = 0.01) during pregnancy compared with postpartum. The median (range) Cmin was 1000 ng/ml (429-5190) and the change in Cmax was not statistically significant (p = 0.07). However, when stratified for CYP2B6 516G>T status, EFV CL/F increased by 100% during pregnancy compared with postpartum (p = 0.001) in patients with the CYP2B6 516GG genotype. The AUC0-24, Cmax and Cmin were reduced by 50.6% (p = 0.001), 17.2% (p = 0.14) and 61.6% (p = 0.003) during pregnancy, with values of 25,900 ng.hr/ml (21,700-32,600), 2640 ng/ml (1260-3490) and 592 ng/ml (429-917), respectively (Table 1).

Conclusions: The clinical relevance of these findings is uncertain, since dose-reduction of EFV in non-pregnant adults was previously not associated with increased risk of virological failure. Nevertheless, the impact of pharmacogenetic variability on mother-to-child transmission of HIV should be further studied.

  Clearance/F (L/hr) AUC0-24 (ng.hr/ml) Cmax (ng/ml) Cmin (ng/ml)
All (CYP2B6 516GG, GT and TT)        
Pregnancy (n = 25) 14.1 (2.96-27.7) 42,600 (21,700-203,000) 3490 (1260-14400) 1000 (429-5190)
Postpartum (n = 19) 9.89 (3.39-20.7) 60,700 (29,000-177,000) 4850 (2050-9760) 2030 (755-6740)
Pregnancy vs Postpartum: % change 42.6 -29.8 -28.0 -50.7
p value 0.023 0.023 0.072 0.012
CYP2B6 516GG        
Pregnancy (n = 8) 23.2 (18.4-27.7) 25,900 (21,700-32,600) 2640 (1260-3490) 592 (429-917)
Postpartum (n = 6) 11.6 (9.37-18.4) 52,400 (32,600-64,000) 3190 (2700-3800) 1540 (867-2310)
Pregnancy vs Postpartum: % change 100 -50.6 -17.2 -61.6
p value 0.0013 0.0013 0.14 0.0027
CYP2B6 516GT        
Pregnancy (n = 14) 13.7 (2.96-23.3) 43,900 (25,700-203,000) 3660 (2490-14400) 1120 (571-5190)
Postpartum (n = 7) 11.9 (4.71-20.67) 50,700 (29,000-128,000) 4850 (2050-6780) 1520 (755-4860)
Pregnancy vs Postpartum: % change 15.1 -13.4 -24.5 -26.3
p value 0.85 0.85 0.43 0.63
CYP2B6 516TT        
Pregnancy (n = 3) 6.83 (5.22-8.15) 87,900 (73,700-115,000) 5770 (5320-5950) 2890 (2660-4030)
Postpartum (n = 6) 4.69 (3.39-5.35) 129,000 (112,000-177,000) 6940 (6370-9760) 5130 (3830-6740)
Pregnancy vs Postpartum: % change 45.6 -31.9 -16.9 -43.7
p value 0.095 0.095 0.024 0.048

*Values are presented as median (range) and p values are for Mann-Whitney U test.